2022
DOI: 10.13040/ijpsr.0975-8232.13(6).2221-29
|View full text |Cite
|
Sign up to set email alerts
|

Untitled

Abstract: As new treatments and medication are growing rapidly, neurologists are also toward expanding treating patients with idiopathic Parkinson's disease and facing questions regarding cannabis as a treatment elective, particularly for levodopa-safe Parkinson's symptoms. Cannabinoids compounds like delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) are the most abundant chemicals present. Whereas THC is psychotropic chemical that tends to cause individuals to feel "high," while CBD is no psychotropic chemical. … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 43 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?